Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate

Chemical Biology and Drug Design

Volumn 83, Issue 3, 2014, Pages 259-265

  Oraki Kohshour, Mojtaba ^a   Mirzaie, Sako ^b   Zeinali, Majid ^c   Amin, Mansour ^a   Said Hakhamaneshi, Mohammad ^d   Jalaili, Ali ^d   Mosaveri, Nader ^e   Jamalan, Mostafa ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c RESEARCH INSTITUTE OF PETROLEUM INDUSTRY RIPI   (Iran)

^d KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

Author keywords

HER2 receptor; multiwalled carbon nanotubes; nano immunoconjugate; thermal ablation; trastuzumab

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN CONJUGATE; MULTI WALLED NANOTUBE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABSORPTION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOTOXICITY; HEAT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION;

HER2 RECEPTOR; MULTIWALLED CARBON NANOTUBES; NANO-IMMUNOCONJUGATE; THERMAL ABLATION; TRASTUZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIPHTHERIA TOXIN; DRUG CARRIERS; FEMALE; HUMANS; INFRARED RAYS; MCF-7 CELLS; NANOTUBES, CARBON; TEMPERATURE;

EID: 84896715742     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12244     Document Type: Article

References (35)

1. Yarden Y., (2001) Biology of HER2 and its importance in breast cancer. Oncology; 61 (Suppl 2): 1-13.
2. Salomon D.S., Brandt R., Ciardiello F., Normanno N., (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol; 19: 183-232.
3. Harari P.M., (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer; 11: 689-708.
4. Nicholson R.I., Gee J.M., Harper M.E., (2001) EGFR and cancer prognosis. Eur J Cancer; 37 (Suppl 4): S9-S15.
5. Mendelsohn J., (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer; 8: 3-9.
6. Yarden Y., (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer; 37 (Suppl 4): S3-S8.
7. Grant S., Qiao L., Dent P., (2002) Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci; 7: d376-d389.
8. Wiley H.S., (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res; 284: 78-88.
9. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr,., Leahy D.J., (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature; 421: 756-760.
10. Schroeder J.A., Lee D.C., (1998) Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ; 9: 451-464.
11. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L., (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science; 235: 177-182.
12. Moasser M.M., (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene; 26: 6469-6487.
13. Shepard H.M., Jin P., Slamon D.J., Pirot Z., Maneval D.C., (2008) Herceptin. Handb Exp Pharmacol; 18: 3-219.
14. Carter P.J., (2006) Potent antibody therapeutics by design. Nat Rev Immunol; 6: 343-357.
15. Govindan S.V., Goldenberg D.M., (2012) Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther; 12: 873-890.
16. Weissleder R., (2001) A clearer vision for in vivo imaging. Nat Biotechnol; 19: 316-317.
17. Kuiyang J., Schadler S.L., Siegel R.W., Xinjie Z., Haifeng Z., Mauricio T., (2003) Protein immobilization on carbon nanotubes via a two-step process of diimide-activated amidation. J Mater Chem; 14: 37-39.
18. Chen J., Hamon M.A., Hu H., Chen Y., Rao A.M., Eklund P.C., Haddon R.C., (1998) Solution properties of single-walled carbon nanotubes. Science; 282: 95-98.
19. Xiuling L., Yuhong X., Chunyang Z., Guifeng Z., Zhiguo S., (2066) Ethylene glycol diglycidyl ether as a protein cross-linker: a case study for cross-linking of hemoglobin. J Chem Technol Biotechnol; 81: 767-775.
20. Hermanson G.T., (2008) Bioconjugate Techniques, 2nd edn. London: Academic.
21. Xiao Y., Gao X., Taratula O., Treado S., Urbas A., Holbrook R.D., Cavicchi R.E., Avedisian C.T., Mitra S., Savla R., Wagner P.D., Srivastava S., He H., (2009) Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC Cancer; 9: 351.
22. Xiao Y., Gao X., Gannot G., Emmert-Buck M.R., Srivastava S., Wagner P.D., Amos M.D., Barker P.E., (2008) Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int J Cancer; 122: 2178-2186.
23. Ross J.S., Schenkein D.P., Pietrusko R., Rolfe M., Linette G.P., Stec J., Stagliano N.E., Ginsburg G.S., Symmans W.F., Pusztai L., Hortobagyi G.N., (2004) Targeted therapies for cancer 2004. Am J Clin Pathol; 122: 598-609.
24. Lambert J.M., (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol; 5: 543-549.
25. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R., (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res; 7: 1490-1496.
26. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., Karanes C., et al,. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol; 19: 3244-3254.
27. Smith A.L., Nicolaou K.C., (1996) The enediyne antibiotics. J Med Chem; 39: 2103-2117.
28. Yu T.W., Bai L., Clade D., Hoffmann D., Toelzer S., Trinh K.Q., Xu J., Moss S.J., Leistner E., Floss H.G., (2002) The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. Proc Natl Acad Sci U S A; 99: 7968-7973.
29. Francisco J.A., Cerveny C.G., Meyer D.L., Mixan B.J., Klussman K., Chace D.F., Chace D.F., et al,. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood; 102: 1458-1465.
30. Chari R.V., (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res; 41: 98-107.
31. Kreitman R.J., (2006) Immunotoxins for targeted cancer therapy. AAPS J; 8: E532-E551.
32. Yamaizumi M., Mekada E., Uchida T., Okada Y., (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell; 15: 245-250.
33. Potala S., Sahoo S.K., Verma R.S., (2008) Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov Today; 13: 807-815.
34. Chakravarty P., Marches R., Zimmerman N.S., Swafford A.D., Bajaj P., Musselman I.H., Pantano P., Draper R.K., Vitetta E.S., (2008) Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc Natl Acad Sci U S A; 105: 8697-8702.
35. Marches R., Chakravarty P., Musselman I.H., Bajaj P., Azad R.N., Pantano P., Draper R.K., Vitetta E.S., (2009) Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies. Int J Cancer; 125: 2970-2977.